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Background: The predictive value of thymidylate synthase (TS) for clinical sensitivity to pemetrexed-containing
chemotherapy in patients with non-small cell lung cancer (NSCLC) remains controversial. This meta-analysis is
performed to provide an assessment of whether expression variations of TS are associated with objective response
in patients with NSCLC treated with pemetrexed-containing chemotherapy.
Methods: An electronic search was conducted using the databases MEDLINE, EMBASE and CNKI, from inception to
June 10th, 2013. A systemic review of the studies on the association between TS expression in NSCLC and objective
response of pemetrexed-containing regimen was performed. Pooled odds ratios (OR) for the response rate were
calculated using the software Revman 5.0.
Results: There were a total of 526 patients in the eight studies that met our criteria for evaluation. +/high
expression of TS was found in 269 patients (51.1%), and -/low expression for this gene was found in 257 (48.9%)
patients. The objective response rate for pemetrexed-containing chemotherapy was significantly higher in patients
with -/low expression TS expression (OR = 0.45; 95% CI, 0.29–0.70; p = 0.0004). Although patients with -/low
expression of TS have a longer median overall survival time and progression free survival time than those with +/high
expression of TS, the difference was not statistically significant.
Conclusions: −/low expression of TS was associated with higher objective response in NSCLC patients treated
with pemetrexed-containing chemotherapy. TS may be a suitable marker of sensitivity to pemetrexed-based
chemotherapy in patients with NSCLC.
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Lung cancer is the most-common cause of cancer-related
mortality worldwide and non-small cell Lung cancer
(NSCLC) accounts for more than 85% of primary lung
cancers and approximately two-thirds of NSCLC patients
are diagnosed at an advanced stage [1-3]. Platinum-based
chemotherapy is appropriate for selected patients who* Correspondence: zhangjie2289@hotmail.com; hqchen1@yahoo.com
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reproduction in any medium, provided the orhave a good performance status [4,5]. But the approach
of treating patients with a platinum-containing regimen
may have reached a plateau in terms of efficacy [6].
Most patients receiving front-line chemotherapy may
experience disease progression and need second-line
therapy [7]. One of several treatments for NSCLC as the
second line therapy is pemetrexed, which is increasing
its therapeutic scope from second-line therapy to first-line
and maintenance therapy [8-10].
Pemetrexed is a multitargeted antifolate agent, inhi-
biting at least three of the enzymes involved in DNA
synthesis and folate metabolism: thymidylate synthase
(TS), dihydrofolate reductase (DHFR) and glycinamidetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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them, TS is a key enzyme that catalyzes the methylation of
fluorod UMP, the precursor of DNA synthesis, into dTMP
[13]. Recent in vitro studies demonstrated that lung cancer
cell lines with low thymidylate synthase expression were
highly sensitive to pemetrexed [14-16]. Thymidylate syn-
thase expression in NSCLC has attracted a considerable
attention because of its potential role as a promising pre-
dictor for response to pemetrexed-based chemotherapy.
A number of studies have explored the relationship
between thymidylate synthase expression and overall re-
sponse rate in NSCLC patients, but clinical data about
TS expression and its predictive value in NSCLC pa-
tients receiving pemetrexed -containing chemotherapy
are still inconclusive. There are published reports sup-
porting that significantly higher response rates were as-
sociated with TS-negativity compared with TS-positivity
in patients with NSCLC especially in those with nonsqua-
mous NSCLC treated with pemetrexed-based Chemother-
apy [3,17,18]. However, there are also reports of studies
failed to find such an association [6,19-22]. Recently, sev-
eral studies have demonstrated that high level of TS ex-
pression was associated with poor prognosis, suggesting
that TS expression may be useful to predict survival after
complete resection in p-stage I adenocarcinoma of the
lung [23-25]. Whereas Zheng and colleagues found that
patients with high TS expression actually had significantly
increased overall survival (OS) when compared to patients
with low expression [26]. To determine whether TS ex-
pression is associated with objective response in NSCLC
patients treated with pemetrexed-containing therapy,
we reviewed published studies and carried out a meta-
analysis.Methods
Search strategy
The search was performed by consulting the electronic
database MEDLINE, EMBASE and CNKI f or all relevant
papers published from the earliest publication date in-
cluded in the database onward to June 10th 2013. Searches
included the terms TS OR thymidylate synthase and lung
cancer. The results were then hand searched for eligible
studies. No language restrictions were imposed. The refer-
ences of retrieved articles were also screened for relevant
articles and two authors (L Wang and R Wang) conducted
all searches independently.Eligibility criteria
The following criteria for eligibility among studies were
set before collecting articles: (1) utilized pemetrexed –
containing chemotherapy for patients with pathologically
proven NSCLC. (2) measured TS with immunohisto-
chemistry (IHC) or real-time reverse transcriptase PCR(RT-PCR); (3) presented the data of objective response
according to TS status.
Quality assessment
Two investigators (L Wang and J Zhang) independently
assessed the quality of each study using the Newcastle–
Ottawa Quality Assessment Scale. Discrepancies were
resolved by consensus. The Newcastle–Ottawa Quality
Assessment Scale involves assessing three categories –
patient selection, study comparability and outcome–based
on eight items. Stars awarded to high-quality elements are
used to compare study quality in a qualitative manner.
Four items in the selection category, two items in the
comparability and three items in the outcome category; a
maximum of two stars can be given for comparability; a
study can be awarded one star for each item in these cat-
egories. The scoring system was recommended by the
Cochrane Non-randomized Studies Methods Working
Group [27,28].
Statistical analysis
Two independent reviewers extracted the required infor-
mation using pre-determined forms. Data on objective
response rate were analyzed. The data were entered into
the Cochrane Collaboration software (RevMan Version
5.0 for Windows; the Cochrane Collaboration, Oxford,
UK) and the Cochran’s test was used to assess the het-
erogeneity of included studies. For the heterogeneity
tests, a P-value below 0.05 was considered to indicate
significance. If the test of heterogeneity was significant
(p < 0.05, I2 > 50%) the random-effect model would be
used, otherwise the fixed model would be used. Publica-
tion bias was estimated by examining the relationship
between the treatment effects and the standard error of
the estimate (S.E log OR) using a funnel plot. Several
additional sensitivity analyses (chemotherapy regimens
and TS measurement methods) were also performed to
further detect and evaluate clinical heterogeneity.
Results
Selection of studies
The search strategy identified 613 potentially relevant
articles, 178 of which were excluded after the titles were
reviewed. A total of 435 studies were included for
abstract review after the first exclusion. Among the 435
studies, 56 of them were not relevant to clinical chemo-
therapy (only illustrating the TS expression and its clini-
copathological correlation to NSCLC) and 98 of them
were not relevant to NSCLCS (studying TS in small cell
lung cancer, neuroendocrine, malignant pleural meso-
thelioma, thymic tumors, primary colorectal cancer, and
so on). There were also 109 review articles in the 435
studies above. So 263 articles were excluded and 172
studies were extracted for full text review after careful
Figure 1 Flow chart of article selection in this meta-analysis: eight studies involving 526 patients were analyzed.







Bepler et al. [6] 4 2 3
Chang et al. [30] 3 2 3
Chen et al. [21] 4 2 3
Igawa et al. [31] 3 2 3
Park et al. [22] 3 2 3
Sun et al. [17] 4 2 3
Takezawa et al. [18] 3 2 3
Wang et al. [19] 3 2 3
The Newcastle–Ottawa Quality Assessment Scale is composed of three
categories, selection, comparability and outcome. Stars are awarded to
high-quality elements and are used to compare study quality in a quantitative
manner. There are four items in the Selection category and three items in the
Outcome category; a study can be awarded one star for each item in these
categories. A maximum of two stars can be given for comparability.
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sufficient information or methods discrepancies. After
completing the selection process, data from a total of
eight studies involving 526 patients (Figure 1) systemat-
ically was analyzed. All of them studied the association
between TS expression and response to pemetrexed-
containing chemotherapy [6,22-31].
The Newcastle–Ottawa Scale, composing of eight items
that assess patient selection, study, comparability and out-
come, was used to conduct the quality assessments for the
eight studies. This scale has been adopted in other non-
randomized studies [28,32,33]. Studies which met five or
more of the eight criteria were given higher quality scores.
A summary of the studies which scored highly is
shown in Table 1. Characteristics of the eligible stud-
ies are presented in Table 2. Bias assessment was eval-
uated by funnel plot analysis shown in Figure 2 and
the heterogeneity in the 8 studies was not significant
statistically (p = 0.23).
Objective response
All studies reported data on tumor objective response
(Table 2), which included complete and partial tumor re-
sponses, stable disease and progression disease. Because
no heterogeneity was found across studies (Chi2 = 9.39,
p = 0.23; I2 = 25%), the fixed-effects model was used.
Pooled data from these eight studies showed an overall
objective response rate of 19.3% for TS +/high expression
(n = 269) and 30.0% for TS -/low expression (n = 257).
These results indicate a statistically significant favorable
clinical outcome for patients with -/low expression TS.
The pooled odds ratio from the eight studies was 0.45
(OR = 0.45; 95% CI, 0.29–0.70; p =0.0004; Figure 3).Subgroup analysis was conducted based on chemo-
therapy regimen. Six studies described clinical results
with patients treated with pemetrexed monotherapy or
pemetrexed plus gemcitabine and three clinical studies
described results of patients treated with pemetrexed
plus cisplatin or carboplatin. For the regimen of peme-
trexed monotherapy or pemetrexed plus gemcitabine, the
overall objective response rate for patients with -/low TS
expression was higher than that for patients with +/high
TS expression(OR = 0.54, 95% CI 0.33–0.91, p = 0.02).
For patients treated with pemetrexed plus cisplatin or
carboplatin, a significantly better objective response rate
was also observed in patients with -/low TS expression
(OR = 0.27, 95% CI 0.10–0.70, p = 0.007). There existed no
heterogeneity between two treatment subgroups (I2 = 12%)
Table 2 Characteristics of studies included in the meta-analysis
Study All pts TS detection
method
Chemotherapy regimen Ethnicity TS expression Evaluable for
response
Disease stage ECOGPS TS high/+ TS low/-
OR (pts) Total pts OR (pts) Total pts
Bepler et al. [6] 52 RT-PCR pemetrexed + gemcitabine Caucasian 35 35 I-III NR 5 17 7 18
Chang et al. [30] 110 IHC pemetrexed Asian 55 52 advanced or reoccurent 0-4 23 41 4 11
Chen et al. [21] 268 IHC pemetrexed Asian 49 42 IIIB-IV NR 3 20 5 22
Park et.al [22] 98 IHC pemetrexed Asian 98 88 IB,IIIA-IV NR 5 54 5 34
Takezawa et al. [18] 24 IHC pemetrexed + platinum Asian 24 24 IIIB-IV 0-1 1 12 6 12
Wang et al. [19] 38 RT-PCR pemetrexed + platinum Asian 38 38 IIIB-IV 0-1 2 10 11 28
Igawa et al. [31] 104 IHC pemetrexed Asian 54 54 IIIB-IV or reoccurent 0-3 0 23 5 31
Sun et al. [17] 285 IHC pemetrexed Asian 149 149 IIIB-IV 0-1 9 75 21 74
pemetrexed + platinum Asian 44 44 IIIB-IV 0-1 4 17 13 27


















Figure 2 Funnel plot for the detection of publication bias.
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ference did not reach statistical significance between
patients treated with platinum-free and platinum contain-
ing subgroup, −/low TS expression patients treated
with pemetrexed plus cisplatin or carboplatin might be
more likely to achieve complete or partial response.
(Figure 4).
Immunohistochemistry (IHC) was used in 6 studies
and real-time reverse transcriptase PCR(RT-PCR) was
used to detect TS in 2 studies and. In IHC subgroup, ob-
jective response rate in TS -/low expression patients was
significantly higher than that in TS +/high expression
patients (OR = 0.44; 95% CI, 0.27–0.71; p = 0.0009). In
Real-time reverse transcriptase PCR subgroup, there was
a trend that TS -/low predicted better objective response
rate, but the difference did not reached statistical signifi-
cance (OR = 0.52; 95% CI,0.18-1.54 p = 0.24). We noted no
evidence of heterogeneity between TS detection method
subgroups in this meta-analysis (Chi2 = 8.33, p = 0.22;
I2 = 28%) (Figure 5).Figure 3 Comparison of objective response rate between the TS -/low
pemetrexed-containing chemotherapy (n = 526). Pooled data from thes
30.0% for TS +/high expression (n = 269) and TS -/low expression (n = 257)
(OR = 0.45; 95% CI, 0.29–0.70; p = 0.0004).Median survival time and time to progression
Median survival data were available in five of 8 studies
on the association between TS expression and response
to pemetrexed-containing chemotherapy [6,17,21,30,31].
Patients with +/high expression of TS had a median
overall survival(OS) time of 14.4 months; patients with
-/low expression of TS had a median overall survival
time of 19.0 months. Although those with -/low expres-
sion of TS have a longer median overall survival time
than those with +/high expression of TS, the difference
was not statistically significant (p = 0.239) (Table 3).
Similar association was also found in five studies that
provide sufficient data for progression free survival time
(PFS) (7.6 months in patients with -/low expression of
TS Vs 5.8 months in patients with +/high expression of
TS, p = 0.13) [6,17,21,30,31] (Table 4).
Discussion
In this meta-analysis, we evaluated the effects of expres-
sion variations in TS on the objective response rate toarm and TS +/high arm of NSCLC patients receiving
e 8 studies showed an overall objective response rate of 19.3% and
, respectively, which was significantly in favor of TS -/low expression
Figure 4 Subgroup analysis by chemotherapy regimen. In the subgroup of the patients treated with pemetrexed plus cisplatin or carboplatin,
overall objective response rate in TS -/low patients was significantly higher than that in TS +/high patients (OR = 0.27, 95% CI 0.10–0.70, p = 0.007). For
the patients treated with pemetrexed monotherapy or pemetrexed plus gemcitabine, the overall objective response rate for patients with -/low TS
expression was significantly higher than that for patients with +/high TS expression(OR = 0.54, 95% CI 0.33–0.91, p = 0.02).
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goal was to test the hypothesis that -/low TS expression
is associated with better objective response rate. Among
the included studies, four of them reported a higher ob-
jective response in the TS -/low expression arm com-
pared with the TS +/high expression arm [6,17,18,31].
While the rest four studies reported no statistically
significant relationship between TS expression and re-
sponse to chemotherapy [19,21,22,30]. We found that
the objective response rate of patients with -/low TS ex-
pression was significantly higher than that in patients
with +/high TS expression. We also conducted a trend
that TS -/low predicted better median survival time and
progression free survival time but without significantFigure 5 Subgroup analysis by TS detection method. In IHC subgroup, o
higher than that in TS +/high expression patients (OR = 0.44; 95% CI, 0.27–
subgroup, there was a trend that TS -/low predicted better objective resp
(OR = 0.52; 95% CI,0.18-1.54 p = 0.24).difference in patients receiving pemetrexed-containing
chemotherapy.
Previous in vitro studies have shown that TS expression
correlated with objective response of NSCLC treated with
pemetrexed-containg chenmotherapy Ozasa et al. [15]
documented that the expression level of the TS gene was
significantly correlated with the concentration of peme-
trexed for 50% cell survival (IC50) in 11 non-small cell
lung cancer cell lines, suggesting up-regulation of the ex-
pression of the TS gene may have an important role in the
acquired resistance to pemetrexed. Wu et al. found down-
ing stream of TS gene may serve as new biomarkers for
predicting responsiveness to pemetrexed [13]. Similar re-
sults were also reported by Chiappori in small cell lungbjective response rate in TS -/low expression patients was significantly
0.71; p = 0.0009). And in Real-time reverse transcriptase PCR
onse rate, but the difference did not reached statistical significance
Table 3 Median overall survival time in the studies
Study Median survival
time(months)
Median ratio p value
TS +/high TS -/low
Bepler et al. [6] 27.8 27 0.97 0.272
Chang et al. [30] 6.7 9.5 1.42 0.688
Chen et al. [21] 10 21.4 2.14 0.09
Sun et al. [17] 18.9 22.3 1.18 0.106
Igawa et al. [31] 8.6 14.7 1.71 0.04
Pool 14.4 19.0 1.32(95% CI 0.92-2.72) 0.24
Patients with +/high expression of TS who received pemetrexed-based
chemotherapy had a median overall survival time of 14.4 months; patients
with -/low expressionof TS had a median overall survival of 19.0 weeks.
Although patients with -/low expression of TS perform a longer median overall
survival time than those with +/high expression of TS, the difference was not
statistically significant (p = 0.24).
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data indicated that the quality of response to pemetrexed-
containing chemotherapy was significantly higher in pa-
tients with -/low TS expression than those with +/high TS
expression (OR = 0.46, 95% CI 0.29-0.72, p =0.0007). Inter-
estingly, subgroup analysis based on whether platinum
was conducted in their performance demonstrated -/low
TS expression was associated a good objective response
rate in platinum-containing subgroup. The knowledge
gained from this subgroup analysis implys that treatment
with pemetrexed plus cisplatin or carboplatin chemother-
apy regimen may be more beneficial for -/low TS expres-
sion patient with NSCLC, compared with pemetrexed
monotherapy regimen or pemetrexed plus gemcitabine.
The reason is thought to be that platinum may play an
important role in the association of TS expression and
overall objective response. Published study has shown
that cisplatin binds to DNA and induces DNA cross-





Median ratio p value
TS +/high TS -/low
Bepler et al. [6] 20.7 21 1.01 0.187
Chang et al. [29] 1.3 2.4 1.85 0.407
Chen et al. [21] 3.4 4.8 1.41 0.01
Sun et al. [17] 2 4.1 2.05 0.001
Igawa et al. [30] 1.6 5.8 3.63 0.03
Pool 5.8 7.6 1.31(95% CI 0.43-2.19) 0.13
Patients with +/high expression of TS who received pemetrexed-based
chemotherapy had a median progression free survival time of 5.8 months;
patients with -/low expressionof TS had a median progression free survival
time of 7.6 months. Although there was a trend that TS -/low predicted better
progression free survival time, the difference did not reached statistical
significance (p = 0.13).breaks and causes cell death [35]. Pemetrexed inhibits
DNA and RNA synthesis by impairing the activity of at
least 3 enzymes, TS, GARFT and DHFR, in the folate
metabolic pathway, a critical pathway for purine and pyr-
imidine synthesis [36]. In vitro sensitivity to platinum-
derived drugs, cisplatin or carboplatin have been reported
to be associated with expression of TS in human lung can-
cer [37]. Recent studies also demonstrated that cisplatin
and pemetrexed may have a synergistic effect and low TS
expression does not necessarily correlate with pemetrexed
sensitivity [38]. Multiple mechanisms may underlie natural
and acquired resistance to pemetrexed [37]. However,
evaluation of a larger data set containing more prospective
studies would provide greater confidence in efficacy be-
tween the two subgroups.
Different bio-methods were analyzed for their abilities
to predict the treatment outcome. IHC detects TS ex-
pression at protein level, while RT-PCR assays at mRNA
level. Several studies have reported some discrepancy
between mRNA expression and protein expression for
TS [24,39,40]. A recent research by Hou.et.al found that
very high protein expression of TS determined by IHC
correlates well with TS mRNA expression, while low
protein expression of TS correlates poorly with TS mRNA
expression [41]. In our meta-analysis, IHC seemed to be
better than RT-PCR to predict objective responsive rate
for lung cancer patients receiving pemetrexed-containing
treatments. TS at the protein level help DNA synthesis
and repair DNA double-strand breaks [42]. We think
that’s the possible reason why IHC is better to predict the
response rate than RT-PCR . Transcription, posttranscrip-
tional regulation, translation, post-translation processing
of the protein may also contribute to the difference. More
prospective studies with large sample size are needed to
further evaluate RT-PCR assay for TS detection and its
power to predict chemotherapy sensitivity.
Intriguingly, although there was a trend that TS -/low
predicted better median overall survival time and progres-
sion free survival time, the difference did not reached stat-
istical significance [25]. Recent studies have reported that
intratumoral TS expression was significantly related to the
prognosis in patients with mesothelioma [43], gastric can-
cer [44] and colorectal cancer [45-47]. For NSCLC, low
TS mRNA level was associated with a better PFS in stage I
and II patients [48]. In our analysis, most patients available
for evaluating median OS and PFS suffered from advanced
or recurrent lung cancer and that may be the possible rea-
son why no significant difference was found between pa-
tients with -/low an +/high expression.
The study has many limitations. Only eight studies are
eligible for our meta-analysis and the sample size analyzed
in each group was relatively small. However, this is the first
and initial meta-analysis of assessment whether TS expres-
sion is associated with objective response in patients with
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More published studies will be helpful in clarifying whether
this is a true association. There was no observed significant
heterogeneity among the included studies (I2 = 25%), we
further explored heterogeneity by conducting subgroup
analyses. Although significant heterogeneity was not
found either, heterogeneity in IHC subgroup was mod-
erately high at 45%, which was mainly due to the diver-
sity of regimen combinations and different populations.
Publication bias is also a possible limitation because
studies that report negative results are published less
frequently than those reporting positive results or those
consistent with prevailing theories [49]. However, we
did not find that publication bias significantly influences
our result of the meta-analysis.
Conclusion
In conclusion, this meta-analysis provided us with evi-
dence that -/low TS expression is associated with a higher
objective response rate for NSCLC patients treated with
pemetrexed-containg chemotherapy. Our results may be
useful in matching NSCLC patients with suitable drugs
and predict response rate to pemetrexed-containg chemo-
therapy as well as for the further investigation of random
clinical trial on patients receiving platinum-based or
pemetrexed-based chemotherapy.
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